Search Orphan Drug Designations and Approvals
-
Generic Name: | Ampreloxetine |
---|---|
Date Designated: | 05/09/2023 |
Orphan Designation: | Treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Theravance Biopharma Ireland Limited Ten Earlsfort Terrace Dublin 2 D02 T380 Ireland The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-